SEARCH

SEARCH BY CITATION

References

  • 1
    Turner H, Kinet JP. Signalling through the high-affinity IgE receptor Fc epsilonRI. Nature 1999;402: B2430.
  • 2
    Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol 1991;9: 457492.
  • 3
    Kay AB. Allergy and Allergic Diseases. Oxford, UK: Blackwell Science, 1997.
  • 4
    Henderson LL, Larson JB, Gleich GJ. Maximal rise in IgE antibody following ragweed pollination season. J Allergy Clin Immunol 1975;55: 1015.
  • 5
    Niederberger V, Niggemann B, Kraft D, Spitzauer S, Valenta R. Evolution of IgM, IgE and IgG(1-4) antibody responses in early childhood monitored with recombinant allergen components: implications for class switch mechanisms. Eur J Immunol 2002;32: 576584.
  • 6
    Herz U, Ahrens B, Scheffold A, Joachim R, Radbruch A, Renz H. Impact of in utero Th2 immunity on T cell deviation and subsequent immediate-type hypersensitivity in the neonate. Eur J Immunol 2000;30: 714718.
  • 7
    Shields RL, Whether WR, Zioncheck K, O'Connell L, Fendly B, Presta LG et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995;107: 308312.
  • 8
    Kruse N, Tony HP, Sebald W. Conversion of human interleukin-4 into a high affinity antagonist by a single amino acid replacement. Embo J 1992;11: 32373244.
  • 9
    Noon LC. B. Prophylactic inoculation against hayfever. Lancet 1911;1: 15721573.
  • 10
    Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998;102: 157164.
  • 11
    Stewart GE 2nd, Lockey RF. Systemic reactions from allergen immunotherapy. J Allergy Clin Immunol 1992;90: 567578.
  • 12
    Wolf BL, Hamilton RG. Near-fatal anaphylaxis after Hymenoptera venom immunotherapy. J Allergy Clin Immunol 1998;102: 527528.
  • 13
    Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341: 468475.
  • 14
    Gurunathan S, Wu CY, Freidag BL, Seder RA. DNA vaccines: a key for inducing long-term cellular immunity. Curr Opin Immunol 2000;12: 442447.
  • 15
    Hartl A, Kiesslich J, Weiss R, Bernhaupt A, Mostbock S, Scheiblhofer S et al. Isoforms of the major allergen of birch pollen induce different immune responses after genetic immunization. Int Arch Allergy Immunol 1999;120: 1729.
  • 16
    Raz E, Tighe H, Sato Y, Corr M, Dudler JA, Roman M et al. Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization. Proc Natl Acad Sci USA 1996;93: 51415145.
  • 17
    Slater JE, Paupore E, Zhang YT, Colberg-Poley AM. The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine. J Allergy Clin Immunol 1998;102: 469475.
  • 18
    Hartl A, Kiesslich J, Weiss R, Bernhaupt A, Mostbock S, Scheiblhofer S et al. Immune responses after immunization with plasmid DNA encoding Bet v 1, the major allergen of birch pollen. J Allergy Clin Immunol 1999;103: 107113.
  • 19
    Hsu CH, Chua KY, Tao MH, Lai YL, Wu HD, Huang SK et al. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med 1996;2: 540544.
  • 20
    Adel-Patient K, Creminon C, Boquet D, Wal JM, Chatel JM. Genetic immunisation with bovine beta-lactoglobulin cDNA induces a preventive and persistent inhibition of specific anti-BLG IgE response in mice. Int Arch Allergy Immunol 2001;126: 5967.
  • 21
    Peng HJ, Su SN, Chang ZN, Chao PL, Kuo SW, Tsai LC. Induction of specific Th1 responses and suppression of IgE antibody formation by vaccination with plasmid DNA encoding Der f 11. Vaccine 2002;20: 17611768.
  • 22
    Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan – DNA nanoparticles generates immunologic protection in a murine model of peanut allergy [see comments]. Nat Med 1999;5: 387391.
  • 23
    Ross TM, Xu Y, Bright RA, Robinson HL. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol 2000;1: 127131.
  • 24
    Faquim-Mauro EL, Coffman RL, Abrahamsohn IA, Macedo MS. Cutting edge: mouse IgG1 antibodies comprise two functionally distinct types that are differentially regulated by IL-4 and IL-12. J Immunol 1999;163: 35723576.
  • 25
    Maecker HT, Hansen G, Walter DM, DeKruyff RH, Levy S, Umetsu DT. Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model. J Immunol 2001;166: 959965.
  • 26
    Jilek S, Barbey C, Spertini F, Corthesy B. Antigen-independent suppression of the allergic immune response to bee venom phospholipase A(2) by DNA vaccination in CBA/J mice. J Immunol 2001;166: 36123621.
  • 27
    Hochreiter R, Stepansoka T, Ferreira F, Valenta R, Vrtala S, Thalhamer J et al. Prevention of Allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch pollen allergen. Eur J Immunol 2003;33: 16671676.
  • 28
    Valenta R. The future of antigen-specific immunotherapy of allergy. Nat Rev Immunol 2002;2: 446453.
  • 29
    Frost L, Johansen P, Pedersen S, Veien N, Ostergaard PA, Nielsen MH. Persistent subcutaneous nodules in children hyposensitized with aluminium-containing allergen extracts. Allergy 1985;40: 368372.
  • 30
    Li X, Huang CK, Schofield BH, Burks AW, Bannon GA, Kim KH et al. Strain-dependent induction of allergic sensitization caused by peanut allergen DNA immunization in mice. J Immunol 1999;162: 30453052.
  • 31
    Hochreiter R, Hartl A, Freund J, Valenta R, Ferreira F, Thalhamer J. The influence of CpG motifs on a protein or DNA-based Th2-type immune response against major pollen allergens Bet v 1a, Phl p 2 and Escherichia coli-derived beta-galactosidase. Int Arch Allergy Immunol 2001;124: 406410.
  • 32
    Weiss R, Leitner WW, Scheiblhofer S, Chen D, Bernhaupt A, Mostbock S et al. Genetic vaccination against malaria infection by intradermal and epidermal injections of a plasmid containing the gene encoding the Plasmodium berghei circumsporozoite protein. Infect Immun 2000;68: 59145919.